| Company Name: |
ATK CHEMICAL COMPANY LIMITED
|
| Tel: |
3429815786 13301662590 |
| Email: |
sales@atkchemical.com |
| Products Intro: |
CAS:1201673-28-0
Purity:98% Package:1G,5G,100G,500g,1kg
|
|
| Product Name: | BPKDi | | Synonyms: | BPKDi;[2,4'-Bipyridine]-4-carboxamide, 2'-(cyclohexylamino)-6-(1-piperazinyl)- | | CAS: | 1201673-28-0 | | MF: | C21H28N6O | | MW: | 380.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1201673-28-0.mol |  |
| | BPKDi Chemical Properties |
| Boiling point | 633.1±55.0 °C(Predicted) | | density | 1.226±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: soluble | | form | A solid | | pka | 14.86±0.50(Predicted) | | color | Off-white to light yellow |
| | BPKDi Usage And Synthesis |
| Biological Activity | BPKDi is an inhibitor of protein kinase D (PKD; IC50s = 1, 9, and 1 nM for PKD1, PKD2, and PKD3, respectively).1 It is selective for PKD over PKCδ and PKCε, as well as over a panel of additional calcium/calmodulin-dependent protein kinase (CaMK) superfamily members, at 1 μM. It inhibits phenylephrine-induced phosphorylation and nuclear export of histone deacetylase 4 (HDAC4) and HDAC5 in, as well reduces phenylephrine-induced hypertrophy of, isolated neonatal rat ventricular myocytes when used at a concentration of 1 μM. | | References | 1.Monovich, L., Vega, R.B., Meredith, E., et al.A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinaseFEBS Lett.584(3)631-637(2010) |
| | BPKDi Preparation Products And Raw materials |
|